Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Daratumumab + Ixazomib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 9||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04052880||Phase II||Daratumumab + Ixazomib Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide||Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM||Recruiting||USA||0|